Dry powder formulations of epinephrine and associated methods
AssigneeBelhaven BioPharma Inc.
InventorsScott Lyman, Brian Taubenheim
Life of this patent
Estimating the term…
Abstract
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Claims20
A method of intranasally delivering a dry powder pharmaceutical composition, comprising:
- intranasally administering, via an intranasal device, a dose of the dry powder pharmaceutical composition to deliver the dose of the dry powder pharmaceutical composition into a body, wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof and a carrier;
- wherein a target delivery percentage of a total mass of the delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited on a turbinate region and an olfactory region is greater than about 74%;
- wherein the target delivery percentage is independent of an orientation of the body and a presence of a respiratory airflow through a nasal passage;
- and
- wherein the delivered dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns.
A method of intranasally delivering a dry powder pharmaceutical composition, comprising:
- intranasally administering, via an intranasal device, a dose of the dry powder pharmaceutical composition to deliver the dose of the dry powder pharmaceutical composition into a body, wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof;
- wherein a target delivery percentage of a total mass of the delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited on a turbinate region and an olfactory region is greater than about 74%;
- wherein the target delivery percentage is independent of an orientation of the body and a presence of a respiratory airflow through a nasal passage;
- wherein a downstream percentage of the total mass of the delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited downstream of a nasopharynx is less than about 5%;
- wherein the downstream percentage is independent of the orientation of the body and the presence of the respiratory airflow through the nasal passage;
- and
- wherein the delivered dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns.
A dry powder pharmaceutical composition comprising:
- epinephrine or a pharmaceutically acceptable salt thereof;
- and
- a carrier;
- wherein a target delivery percentage of a total mass of delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited on a turbinate region and an olfactory region is greater than about 74%;
- wherein the target delivery percentage is independent of an orientation of a body and a presence of a respiratory airflow through a nasal passage;
- and
- wherein the delivered dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns.
Dependencies are inferred from the claim text.